January 17, 2018 06:15 AM EST
R&D
Pharma

Kym­ri­ah gets speedy re­views in US and EU as No­var­tis looks to swift­ly ex­pand CAR-T in­di­ca­tions

Amber Tong

Equipped with da­ta to di­rect­ly com­pete with Gilead’s $GILD CAR-T, No­var­tis has se­cured promis­es of quick re­views of Kym­ri­ah for a sec­ond in­di­ca­tion in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump team asked Warp Speed leader to head NIH, may seek more tra­di­tion­al pick for role

How did Trump’s FDA pick land? Biotech stocks are up, and ex­ec­u­tives are (most­ly) re­lieved

Bris­tol My­ers re­veals more job cuts in New Jer­sey

Mer­ck halts Phase 3 tri­al with PAH drug Win­re­vair fol­low­ing pos­i­tive in­ter­im da­ta 

In­cyte touts Mon­ju­vi da­ta from Phase 3 fol­lic­u­lar lym­phoma tri­al as it heads to FDA

Gilead buys ex­per­i­men­tal HIV vac­cines from a small Barcelona biotech

A service from the Financial Times